Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAKs). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor, AZD1480, both as a single agent and in combination with...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Cancer Ther
Главные авторы: Suryani, Santi, Bracken, Lauryn S., Harvey, Richard C., Sia, Keith C.S., Carol, Hernan, Chen, I-Ming, Evans, Kathryn, Dietrich, Philipp A., Roberts, Kathryn G., Kurmasheva, Raushan T., Billups, Catherine A., Mullighan, Charles G., Willman, Cheryl L., Loh, Mignon L., Hunger, Stephen P., Houghton, Peter, Smith, Malcolm A., Lock, Richard B.
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326541/
https://ncbi.nlm.nih.gov/pubmed/25504635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0647
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы